http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201605430-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ada68032e6c5599de33d868231aaa52d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C403-02 |
| filingDate | 2014-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a313209d3fb13fd5169616df6ada848e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2081855099dafe0c25e096da668ca8c0 |
| publicationDate | 2016-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201605430-A |
| titleOfInvention | Use of γ-Bisabolene for the treatment of oral cancer |
| abstract | Use of a compound of formula (I) (ie, γ-Bisabolene) for the manufacture of a medicament:n□nAmong them, the agent is used for inhibiting phosphorylation of tissue protein deacetylase 2 (HDAC2) of cancer cells, increasing acetylation of p53 protein of cancer cells, and increasing apoptosis-promoting genes of cancer cells ( The expression of apoptosis-promoting genes and/or the activation of apoptosis-related proteins that stimulate cancer cells. The agent can also be used to inhibit cancer cell growth. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110960518-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110960518-B |
| priorityDate | 2014-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 241.